Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The salt wasting form of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (classical 21 OHD CAH) is characterized by virilization of the external genitalia in females, hypocortisolism, precocious pseudopuberty and renal salt loss due to aldosterone deficiency.
Biomarker and diagnostic research for classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form has been reported in the published literature.
Estimated prevalence: 1-9 in 100,000 (Uncommon).
No clinical trials have been registered for classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form.
11 publications have been identified in PubMed for classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form. Research spans Review / Meta-Analysis (36%), Diagnostic / Biomarker (18%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 4 |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:36 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, salt wasting form
Testing and diagnosis research | 2 | 18% |
Patient case studies | 2 | 18% |
Laboratory research | 2 | 18% |
Disease patterns and progression | 1 | 9% |
Hubska J (2026). [PMID: 41816211](https://pubmed.ncbi.nlm.nih.gov/41816211/). *Front Endocrinol (Lausanne)*. [Case Report / Case Series]
Baronio F (2025). [PMID: 40952600](https://pubmed.ncbi.nlm.nih.gov/40952600/). *J Endocrinol Invest*. [Diagnostic / Biomarker]
Yang M (2025). [PMID: 39836621](https://pubmed.ncbi.nlm.nih.gov/39836621/). *J Clin Endocrinol Metab*. [Review / Meta-Analysis]
Atas N (2025). [PMID: 40552539](https://pubmed.ncbi.nlm.nih.gov/40552539/). *Mol Genet Genomic Med*. [Basic Science / Preclinical]
Aldalaan H (2025). [PMID: 40313490](https://pubmed.ncbi.nlm.nih.gov/40313490/). *Front Endocrinol (Lausanne)*. [Epidemiology / Natural History]
Concolino P (2025). [PMID: 39911519](https://pubmed.ncbi.nlm.nih.gov/39911519/). *J Endocr Soc*. [Review / Meta-Analysis]
Krysiak R (2025). [PMID: 39240753](https://pubmed.ncbi.nlm.nih.gov/39240753/). *Endocr Rev*. [Review / Meta-Analysis]
de Sousa Azulay RS (2025). [PMID: 40149505](https://pubmed.ncbi.nlm.nih.gov/40149505/). *Genes (Basel)*. [Case Report / Case Series]
Odabaşı Güneş S (2025). [PMID: 39713855](https://pubmed.ncbi.nlm.nih.gov/39713855/). *J Clin Res Pediatr Endocrinol*. [Review / Meta-Analysis]
Sarafoglou K (2025). [PMID: 38701341](https://pubmed.ncbi.nlm.nih.gov/38701341/). *J Clin Endocrinol Metab*. [Basic Science / Preclinical]